Quest Diagnostics Incorporated $DGX Shares Sold by SteelPeak Wealth LLC

SteelPeak Wealth LLC decreased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 91.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,252 shares of the medical research company’s stock after selling 13,705 shares during the quarter. SteelPeak Wealth LLC’s holdings in Quest Diagnostics were worth $239,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in DGX. Brighton Jones LLC acquired a new stake in Quest Diagnostics in the fourth quarter valued at approximately $323,000. Vident Advisory LLC grew its holdings in Quest Diagnostics by 31.9% during the 1st quarter. Vident Advisory LLC now owns 3,196 shares of the medical research company’s stock worth $541,000 after acquiring an additional 773 shares in the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Quest Diagnostics in the 1st quarter valued at approximately $76,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Quest Diagnostics by 3.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,221 shares of the medical research company’s stock valued at $4,606,000 after purchasing an additional 860 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its position in shares of Quest Diagnostics by 34.5% during the 1st quarter. NewEdge Advisors LLC now owns 9,521 shares of the medical research company’s stock worth $1,611,000 after purchasing an additional 2,441 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Price Performance

DGX stock opened at $173.75 on Monday. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $19.33 billion, a P/E ratio of 20.39, a PEG ratio of 2.21 and a beta of 0.64. The business has a 50 day simple moving average of $181.30 and a 200-day simple moving average of $179.71. Quest Diagnostics Incorporated has a twelve month low of $148.70 and a twelve month high of $197.55.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, October 21st. The medical research company reported $2.60 EPS for the quarter, beating the consensus estimate of $2.51 by $0.09. The firm had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.73 billion. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. Quest Diagnostics’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.30 EPS. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. As a group, equities analysts anticipate that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Stockholders of record on Tuesday, January 13th will be paid a dividend of $0.80 per share. The ex-dividend date is Tuesday, January 13th. This represents a $3.20 annualized dividend and a dividend yield of 1.8%. Quest Diagnostics’s dividend payout ratio is 37.56%.

Analysts Set New Price Targets

A number of research firms have weighed in on DGX. Piper Sandler raised their price target on Quest Diagnostics from $190.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Barclays raised their target price on Quest Diagnostics from $190.00 to $195.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 22nd. Leerink Partners boosted their target price on Quest Diagnostics from $203.00 to $210.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Morgan Stanley set a $207.00 price target on shares of Quest Diagnostics and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Jefferies Financial Group boosted their price objective on shares of Quest Diagnostics from $200.00 to $215.00 and gave the stock a “buy” rating in a research report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $197.27.

Insider Buying and Selling

In other Quest Diagnostics news, CEO J. E. Davis sold 55,093 shares of Quest Diagnostics stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $192.22, for a total value of $10,589,976.46. Following the transaction, the chief executive officer directly owned 120,480 shares in the company, valued at approximately $23,158,665.60. This trade represents a 31.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Vicky B. Gregg sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $191.76, for a total value of $239,700.00. Following the completion of the transaction, the director directly owned 17,037 shares in the company, valued at approximately $3,267,015.12. The trade was a 6.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 65,771 shares of company stock worth $12,588,676. Insiders own 8.16% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.